TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01487200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FX006 10 mg
Description: single 3 mL IA injection
Study: NCT02774434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JM-105
Description: Measurement of TcB via the JM-105 device
Study: NCT01846936

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DLT with conventional technique
Description: The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BB with conventional technique
Description: The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.~The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Disconnection technique
Description: Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
Study: NCT03608475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limited Ultrasound Imaging
Description: Ultrasound imaging will not be performed at the 2, 5 and 8 week clinic visits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ultrasound Imaging
Description: Ultrasound imaging will be performed at all clinic visits
Study: NCT04484935

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirsevimab
Description: Single fixed IM dose of nirsevimab 50 mg if body weight \< 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
Study: NCT02745873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
Study: NCT02793583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bendamustine
Study: NCT04021290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/3TC FDC
Description: DTG/3TC FDC will be available as white, oval, film-coated tablets at a unit dose strength of 50 mg/300 mg. Participants will take DTG/3TC once daily via oral route.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAR
Description: Participants who are randomized to the CAR arm will continue to take the current treatment until Week 52. CAR will include 2 NTRIs plus either an INI, NNRTI, or boosted PI or atazanavir unboosted.
Study: NCT03487094

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula
Description: Multi-centered, prospective, randomized clinical trial

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula
Description: Multi-centered, prospective, randomized clinical trial
Study: NCT05361850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation
Description: Removal of the endotracheal tube

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation
Description: Removal of the endotracheal tube
Study: NCT02593448

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anaesthesia with propofol use
Description: Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.~Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60.
Study: NCT01664754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study: NCT02593448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anaesthesia with sevoflurane use
Description: Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.~Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.~Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.~Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60.
Study: NCT01664754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study: NCT03289533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab (MSB0010718C)
Description: Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
Study: NCT01030822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, administered as a single dose
Study: NCT01862315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Study: NCT01862315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research blood draws
Description: These are optional

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research blood draws
Description: These are optional

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research blood draws
Description: These are optional
Study: NCT01030822

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, 3 doses
Study: NCT02895815

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CNTO 2476 (6.0 * 10^4 cells)
Description: Participants will receive a single subretinal administration of CNTO 2476 (6.0 \* 10\^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit \[SRAK-02 kit\] and third arm accessory).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CNTO 2476 (3.0 * 10^5 cells)
Description: Participants will receive a single subretinal administration of CNTO 2476 (3.0 \* 10\^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
Study: NCT01649713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluval AB vaccination
Description: Vaccination with Fluval AB suspension for injection
Study: NCT02178098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: ETC-1002 capsules taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken once daily
Study: NCT04243980

Intervention type: DEVICE
Intervention: Short anatomical femoral stem in THR
Description: Patients with osteoarthritis after total hip arthroplasty
Study: NCT00285844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss
Study: NCT02524587

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard polyethylene acetabular irradiated at 3 Mrad

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: radio stereometric analysis (RSA) of the acetabular
Study: NCT00285844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiazolidinedione
Study: NCT03707886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain SMART
Description: Pain SMART is a brief, one-visit shared medical appointment where providers in primary care and a behavioral health specialist (e.g., a psychologist) meet with a group of patients with chronic pain to discuss pain management approaches.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: minimally enhanced usual care
Description: The minimally enhanced usual care group will receive educational information via mail about non-pharmacological approaches to pain management.
Study: NCT02765399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03084718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 718 pMDI
Description: Dose Response: Test one of three different doses of CHF 718 pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 718 pMDI
Description: Dose Response: Test one of three different doses of CHF 718 pMDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF 718 pMDI
Description: Dose Response: Test one of three different doses of CHF 718 pMDI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pMDI
Description: Placebo Control

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone Dipropionate (BDP)
Description: Active Control
Study: NCT01503580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tolterodine, solifenacin
Description: The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
Study: NCT01152736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 2 mg Single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 2 mg Single-dose
Study: NCT02331524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Feedback and Encouragement
Description: The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!
Study: NCT03243227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodynamic techniques
Description: 4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: AROM exercise stretching exercise strengthening exercise 4 sessions
Study: NCT03484728

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo manipulation
Description: application of nonactive body cream on forearm

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: placebo manipulation
Description: application of nonactive body cream on forearm
Study: NCT03272555

Intervention type: OTHER
Group type: OTHER
Intervention: WILD 5 Wellness Interventions
Description: Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
Study: NCT02656667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation
Description: quadriceps strenghthening with neuromuscular electrical stimulation (medical device)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cycle ergometer training
Description: quadriceps strenghthening with cycle ergometer training

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional pulmonary rehabilitation
Description: excercise training on treadmill

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional pulmonary rehabilitation
Description: excercise training on treadmill
Study: NCT01203709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose combination of MMF and Tac
Description: mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
Study: NCT01601184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day

Intervention type: DRUG
Group type: OTHER
Intervention: vismodegib
Description: Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
Study: NCT02067507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored education and referral
Description: LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Staff training and patient reminders
Description: AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; (3) Patient reminders and provider cues for follow-up doses; and (4) Organizational strategies to improve processes for vaccine delivery, in addition to usual care activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic-level reminder systems
Description: Northeast Valley Health Corporation Site: Three different clinic-level reminder systems, including a mailed letter, automated/robo telephone call, or text message reminder
Study: NCT00688857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline
Description: Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazoxide choline
Description: Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
Study: NCT01727388

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lateral decubitus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supine decubitus
Study: NCT04074564

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MASCT-I, Camrelizumab,Apatinib
Description: Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) is a sequential immune cell therapy.~Camrelizumab is an immune checkpoint inhibitors against PD-1.~Apatinib is a highly selective tyrosine kinase inhibitor targeting VEGFR2.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MASCT-I, Camrelizumab,Apatinib
Description: Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) is a sequential immune cell therapy.~Camrelizumab is an immune checkpoint inhibitors against PD-1.~Apatinib is a highly selective tyrosine kinase inhibitor targeting VEGFR2.
Study: NCT02737501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: Brigatinib tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crizotinib
Description: Crizotinib tablets
Study: NCT01252082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Rootplaning
Description: All patients in the test group receive scaling and rootplaning under local anesthesia
Study: NCT02582827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-011
Description: ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
Study: NCT00741169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350
Description: 200 mg taken by mouth once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350
Description: 200 mg taken by mouth once daily for 7 days
Study: NCT00826657

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12
Description: 500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
Study: NCT00741169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350
Description: 200 mg taken by mouth once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350
Description: 200 mg taken by mouth once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350
Description: 200 mg taken by mouth once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435350
Description: 200 mg taken by mouth once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg taken by mouth once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg taken by mouth once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg taken by mouth once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg taken by mouth once daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg taken by mouth once daily for 7 days
Study: NCT00826657

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
Study: NCT02940951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QPSS
Description: Home care providers use the QPSS that includes standardized instruments for assessing patient and family caregiver quality of life in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Home healthcare services provided by nurses and, where applicable, multi-professional teams.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Home healthcare services provided by nurses and, where applicable, multi-professional teams.
Study: NCT04156789

Intervention type: DIAGNOSTIC_TEST
Intervention: Home sleep apnea testing
Description: Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.

Intervention type: DIAGNOSTIC_TEST
Intervention: Home sleep apnea testing
Description: Sarcoidosis patients and control subjects will undergo one night of home sleep apnea testing using ApnoeaLinkTM Plus device (ResMed Corporation, Poway, Calif). The device records the patient's nasal respiratory pressure signal as a surrogate of nasal flow, respiratory movements by a thoracic impedance belt, and finger pulse oximetry. The results of the sleep study will be scored automatically with dedicated software (ResMed Corporation, Poway, Calif), and manually reviewed to ensure data accuracy.
Study: NCT00301652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: MMF,1.0g/d
Study: NCT03336515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group C-Postural device activated
Description: General recommendation not sleeping in supine position and the postural device activated (intervention group).